Indeed, patients who clear the infection upon dual treatment with pegylated-IFN-α + ribavirin (PegIFNα–ribavirin) have lower baseline (pre-treatment) expression of NKp30 and of CD85j, compared to those who subsequently fail the treatment (null responders, partial responders) (64). The gene discussed is NCR3; the disease is infection.